Tag: femoropopliteal disease
PRIZER study to put the spotlight back on bare metal stents
This advertorial is sponsored by Terumo Interventional Systems.
Koen Deloose (Sint Blasius Hospital, Dendermonde, Belgium) talks to Interventional News about the importance of treating femoropopliteal...
CIRSE supports use of paclitaxel-coated devices in femoropopliteal disease treatment
In June 2023, the Cardiovascular Interventional Radiological Society of Europe (CIRSE) published an editorial in Cardiovascular Interventional Radiology (CVIR). Written on behalf of CIRSE’s...
EMINENT one-year results show “superior” primary patency rate for Eluvia DES...
One-year results presented at Vascular Interventional Advances (VIVA) 2021 (5–7 October, Las Vegas, USA) from the EMINENT trial demonstrated the superiority of the Eluvia...
Two-year Ranger DCB data demonstrate “sustained, high rate” of device efficacy
Patients treated with the Ranger drug-coated balloon (DCB; Boston Scientific) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year...
VIVA 2021: IN.PACT Admiral DCB found to provide “high five-year freedom...
Real-world data drawn from the IN.PACT Global study looking at five-year freedom from clinically-driven target lesion revascularisation (TLR) among prespecified chronic total occlusion (CTO),...
